Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Shattuck Labs (NASDAQ: STTK) granted inducement stock options to two newly hired non-executive employees on November 10, 2026.
The awards cover 384,000 common shares at an exercise price of $4.85 per share, with a maximum term of 10 years. Each award vests 25% on the first anniversary of the employee’s start date, followed by equal monthly installments over 36 months. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4). Granted outside the 2020 Equity Incentive Plan, the options generally carry the same terms and conditions as awards under that plan.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.384,000 stock options at a $4.85 exercise price create potential dilution if exercised.
Key Figures
- Option shares
- 384,000 shares
- Aggregate inducement awards
- Exercise price
- $4.85 per share
- Inducement stock options
- Maximum option term
- 10 years
- Stock options
- Vesting schedule
- 25% on the first anniversary; remainder in equal monthly installments over 36 months
- Each employee’s award
Key Terms
non-qualified stock options financial
exercise price financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas and DURHAM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on November 10, 2026 (the “Grant Date”) to two newly-hired non-executive employees.
The inducement awards consist of non-qualified stock options to purchase an aggregate of 384,000 shares of Shattuck’s common stock with an exercise price of
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.